Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) successfully completed foundational phases of development of an antibody construct labeled with actinium-225 using the Company’s novel proprietary APIT (Alpha Particle Immunotherapy Technology) platform. This new pipeline entry further validates the robustness of Actinium’s platform technology. The labeled antibody has the potential to be broadly used in the field of hematology/oncology. Quality control testing of the new construct has confirmed that the product meets or exceeds all specifications related to biological integrity and properties of the labeled antibody. Early animal work has confirmed the biological properties of this new antibody drug conjugate (ADC).

Based on the successful outcome of this first phase in this new development program, collaborating parties are continuing preclinical development of the product leading to clinical trials. The Company is further evaluating biological effectiveness in appropriate animal models and also validating the clinical and market opportunity applicable to this product candidate. Assuming that the clinical and market potential of this antibody construct are confirmed, the Company expects to unveil the development plan and timing for the latest pipeline entry in the fourth quarter of 2015.

Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post surgery. “These initial results confirm that we have a very robust technology that is well protected on all sides with appropriate intellectual property,” said Kaushik J. Dave, Actinium’s President and CEO. “We can now continue moving forward with further development and evaluation of this latest product candidate which expands our pipeline.” (Original Source)

Shares of Actinium Pharmaceuticals closed last Friday at $1.98 . ATNM has a 1-year high of $8.12 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.38 and its 200-day moving average is $3.00.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.